Market research
PGHL.NSE Procter & Gamble Health Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 87B
- P/E ratio
- 24.38
- Analyst target
- 7090
- Dividend yield
- 0.0%
- Beta
- 0.18
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE199A01012
- Market cap
- 87B
- P/E ratio
- 24.38
- Analyst target
- 7090
- Dividend yield
- 0.0%
- Beta
- 0.18
About
About Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceutical and chemical products in India and internationally. It offers over-the-counter products, vitamins, minerals, and supplements under the Betamil, Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen brand names. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. The company operates as a subsidiary of Procter & Gamble Overseas India B.V.
Research context
Procter & Gamble Health Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PGHL.NSE discussion.
5 years, 6 months ago
Procter & Gamble Health Limited is currently in a long term downtrend where the price is trading 9.3% below its 200 day moving average.
From a valuation standpoint, the stock is 140.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 11.5.
Procter & Gamble Health Limited's total revenue rose by 1.5% to $2B since the same quarter in the previous year.
Its net income has increased by 77.6% to $679M since the same quarter in the previous year.
Finally, its free cash flow fell by 51.5% to $734M since the same quarter in the previous year.
Based on the above factors, Procter & Gamble Health Limited gets an overall score of 2/5.